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A substantial proportion of patients with nononcogene-addicted non-small-cell lung cancer (NSCLC)
has ‘aggressive disease’, as reflected in short time to progression or lack of disease control with initial
platinum-based chemotherapy. Recently, clinical correlates of aggressive disease behavior during first-line
therapy have been shown to predict greater benefit from addition of nintedanib to second-line docetaxel
in adenocarcinoma NSCLC. Positive predictive effects of aggressive disease have since been reported with
other anti-angiogenic agents (ramucirumab and bevacizumab), while such features may negatively im-
pact on outcomes with nivolumab in nonsquamous NSCLC with low PD-L1 expression. Based on a review
of the clinical data, we recommend aggressive nonsquamous NSCLC should be defined by progression
within <6–9 months of first-line treatment initiation.
Lay abstract: Chemotherapywith platinum-containing drugswas formany years the standard initial treat-
ment for advanced NSCLC. Today’s treatment options also include drugs that help the immune system to
attack the cancer (‘immunotherapies’). These drugs may be used with or without chemotherapy, depend-
ing on themolecular profile of the tumor. However, many patients have a fast-growing (‘aggressive’) form
of NSCLC and so gain little benefit from initial chemotherapy. This patient subgroup has often been over-
looked in clinical research to date. In this article, we discuss how ‘aggressive NSCLC’ can be defined and
consider how many patients are affected. We also look at the impact of aggressive disease on the effec-
tiveness of other treatments used after initial chemotherapy. Based on a thorough review of the evidence,
we recommend that patients who need to change treatment within 6–9 months of starting initial ther-
apy should be defined as having aggressive NSCLC. We hope this definition can help doctors to recognize
aggressive tumors and adapt treatment accordingly to improve patients’ outcome.
First draft submitted: 18 December 2018; Accepted for publication: 28 January 2019; Published online:
13 February 2019
Keywords: aggressive • anti-angiogenic therapy • non-small-cell lung cancer
Future Oncol. (2019) 15(12), 1363–1383 ISSN 1479-6694 136310.2217/fon-2018-0948 C© 2019 Rolf Kaiser
Perspective Reck et al.
Enormous strides have been made in the management of advanced NSCLC over the past decades [1]. Insights into
the biology and genetics of the disease have yielded novel therapeutic strategies and, in a subset of patients, enable
individualized treatment targeting the oncogenic mutations that drive tumor growth [1–3]. Nevertheless, more than
three quarters of advanced NSCLCs lack an ‘actionable’ driver mutation for which a specific targeted therapy is
approved [3]. For many years, the mainstay of first-line therapy for this population was chemotherapy with a platinum
compound (cisplatin or carboplatin) in combination with a third-generation cytotoxic agent, such as an antitubulin
therapy (docetaxel, paclitaxel, nab-paclitaxel or vinorelbine) or antimetabolite (pemetrexed or gemcitabine) [4–7].
These regimens may be combined with the anti-VEGF antibody bevacizumab for nonsquamous tumors [4,8,9].
For squamous tumors, the EGFR inhibitor necitumumab is approved for use with gemcitabine/cisplatin [4,9]. In
biomarker-unselected populations, first-line platinum-based doublets provide an overall response rate (ORR) of
20–30% and median time-to-progression (TTP) of 3.5–5.5 months [5].
First-line treatment of nononcogene-addicted NSCLC is currently undergoing a significant shift with the
introduction of immunotherapies that reactivate antitumor immunity through inhibition of the PD-1/PD-L1
axis [10–13]. Only the PD-1 inhibitor pembrolizumab is currently approved for first-line use, either as monotherapy
in patients with PD-L1 tumor proportion score (TPS) ≥50% (∼30% of nononcogene-addicted NSCLC) or in
combination with chemotherapy for nonsquamous tumors irrespective of PD-L1 expression [10,14]. The first of these
indications was approved following demonstration of significant overall survival (OS) benefit with pembrolizumab
versus chemotherapy in patients with PD-L1 TPS ≥50% in the Phase III KEYNOTE-024 trial [10,14]. The anti-
PD-1 agent nivolumab, in contrast, failed to demonstrate efficacy as monotherapy when compared with first-line
chemotherapy in a Phase III trial in patients with PD-L1 TPS ≥5% [15].
More recently, both pembrolizumab and the PD-L1 inhibitor atezolizumab have shown significant benefits when
added to first-line chemotherapy (±bevacizumab) in Phase III trials in nonsquamous and squamous NSCLC, ir-
respective of PD-L1 expression level [11,12,16,17]. Nivolumab has also demonstrated efficacy in the first-line setting
when combined with a second immunotherapy, the CTLA-4 blocker ipilimumab, in PD-L1-unselected NSCLC
with high tumor mutational burden [13]. A secondary end point of the same trial showed progression-free survival
(PFS) and response increases with nivolumab plus chemotherapy versus chemotherapy alone in PD-L1-negative
NSCLC regardless of histology or tumor mutational burden [18]. Currently, only pembrolizumab is approved for
use in combination with first-line chemotherapy (for nonsquamous NSCLC) [14], but recent results, guidelines [4]
and potential future regulatory approvals will likely stimulate increasing incorporation of immunotherapies, with
or without chemotherapy, into initial treatment. These tremendous advances raise significant questions for subse-
quent management, since there is little evidence regarding the efficacy of current second-line options after initial
immunotherapy.
First-line chemotherapy provides disease control for most patients with nononcogene-addicted advanced NSCLC,
but almost all will eventually develop progressive disease (PD) [11,15,19]. Although several second-line therapies are
approved, only ∼50–60% of patients in clinical trials go on to receive further therapy and even fewer may receive
second-line treatment in real-world settings [11,15,20,21]. In a German cohort of 804 patients with nononcogene-
addicted nonsquamous NSCLC, only 37% of patients treated with first-line therapy received a second-line regimen
(C Grohe´, Unpublished Observations). Low utilization of second-line therapy likely reflects rapidly declining
clinical condition in a substantial number of patients [22].
Depending on first-line therapy, tumor histology and PD-L1 expression, second-line options can include anti-
angiogenic therapies (nintedanib or ramucirumab) in combination with docetaxel, single-agent immunotherapies
(pembrolizumab, nivolumab or atezolizumab), cytotoxic monotherapy with docetaxel or pemetrexed, the ErbB
family blocker afatinib, or the EGFR inhibitor erlotinib (EGFR wild-type tumors; Figure 1) [4]. With a range
of second-line therapies now approved, there is significant interest in the development of predictive factors to
support clinical decision making. Against this background, systematic analyses of Phase III data for nintedanib for
the first time showed that clinical correlates of ‘aggressive’ disease behavior in the first-line setting had predictive
relevance for the efficacy of subsequent therapy [23]. These observations have since been extended in analyses of
other second-line therapies [24–27].
Given the emerging importance of these clinical markers, this narrative review summarizes current knowledge
regarding aggressive disease in patients with nononcogene-addicted advanced NSCLC. We discuss the concept,
definition, prevalence and clinical features of these tumors, consider the pathophysiological mechanisms that may
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Figure 1. Treatment options for patients with nononcogene-addicted non-small-cell lung cancer.
†Tumors with nonsquamous histology.
‡Only approved for tumors with nonsquamous histology at the time of writing.
§Indication not approved at the time of writing.
‖Tumors with adenocarcinoma histology.
¶Tumors with PD-L1 expression >1%.
#Tumors with squamous histology.
NSCLC: Nononcogene-addicted non-small-cell lung cancer; TMB: Tumor mutational burden.
Adapted with permission from [4].
underlie aggressive disease behavior, and explore how current clinical data may redefine the treatment landscape
for these tumors. Finally, we propose a clinical definition of aggressive disease to help harmonize future research
that aims to improve the identification and management of this under-recognized, and hitherto neglected, patient
population.
Concept of aggressive NSCLC
Every physician treating patients with cancer will have experience of tumors that progress rapidly and are not
amenable to treatment. Due to their short survival times and expectation of treatment refractoriness, these patients
may be under-represented in clinical trials and have never been a focus of intensive research. Moreover, the concept
of aggressive disease remains poorly defined and rarely considered in either preclinical/clinical research or clinical
practice.
In cancer biology, the term ‘aggressive’ is broadly used to describe tumors that develop, progress or metastasize
more quickly [28]. Aggressive disease behavior is, therefore, expected to manifest in poor clinical outcomes, such as
nonresponse, lack of disease control, more rapid TTP and shorter duration of survival. Although associated with
unfavorable outcomes, aggressive disease is not synonymous with poor prognosis per se, as it implies the presence
of a pernicious underlying pathophysiology and excludes patient-related poor prognostic factors, such as age and
performance status (PS) [29]. Clinically, the concept of ‘aggressive disease’ may be useful for identifying a subset of
patients with unfavorable clinical course of disease (prognostic relevance) and/or who may derive particular benefit
from specific therapeutic approaches (predictive relevance).
Analyses to date have utilized operational definitions of aggressive NSCLC to capture early progression on
or after platinum-containing chemotherapy, based on either the timing of second-line therapy or best response
attained during first-line treatment. The former, time-based measures have indexed the second-line baseline either
to the start of first-line therapy (time since start of first-line therapy [TSFLT]) or to the end of first-line therapy
(time since end of first-line therapy; TEFLT), the key difference between these variables being the exclusion of
future science group www.futuremedicine.com 1365
Perspective Reck et al.
the on-treatment period from TEFLT [30]. TSFLT and TEFLT are analogous to the progression-free interval and
platinum-free interval, respectively, which are routinely applied in the classification of small cell lung cancer (SCLC)
and ovarian cancer [31,32]. In NSCLC, TSFLT cut-points of <3 months, ≤5 months and <9 months have been
explored in clinical datasets [25,30,33]. The TSFLT cut-point of <9 months was selected as a potentially optimal
threshold in prognostic and predictive analyses of two Phase III studies of nintedanib [23], while TSFLT ≤5 months
was based on median PFS of ∼5 months reported in interventional and observational NSCLC studies with first-line
platinum-based chemotherapy [30,34,35]. For TEFLT, cut-points of <3 and ≤6 months have been evaluated, which
correspond to definitions of platinum resistance used in SCLC and ovarian cancer, respectively [30–32].
Aggressive disease has also been defined by lack of disease control during initial treatment, as indicated by PD as
best response to first-line therapy (PD-FLT) [25,30,33]. Compared with TSFLT-based definitions, PD-FLT is a more
restrictive categorization because it excludes patients who attain even short-lived responses. These classifications bear
some relation to the definitions of primary (intrinsic) and secondary (acquired) resistance that are used in EGFR
inhibitor-treated NSCLC [36]. Whereas PD-FLT is similar to primary resistance (although primary resistance may
or may not include patients with stable disease [SD]), TSFLT-defined aggressive disease can also include tumors
with secondary resistance depending when resistance emerges [36]. Indeed a key limitation of both TSFLT and
PD-FLT definitions is their inability to distinguish between de novo aggressive disease and treatment resistance.
It is worth noting that ‘refractory disease’ has been used variously to refer to PD-FLT, TSFLT ≤5 months and
TEFLT <3 months [25,30,37]. In this review, we will favor the TSFLT, TEFLT and PD-FLT descriptors throughout
to specify the definition being applied in each case.
The term ‘hyperprogressive disease’ (HPD) has been recently coined to describe a new pattern of nonresponse in
which tumors exhibit a paradoxical acceleration of growth during treatment with immunotherapies [38]. Different
investigators have defined HPD by a >50% or ≥twofold increase in tumor growth rate following immunotherapy
initiation, relative to the pretreatment period [38,39]. HPD is distinguished from usual PD in that it is dependent on
treatment and represents a marked worsening of disease, rather than simple nonefficacy [38]. As a treatment-related
phenomenon, HPD is distinct from the aggressive disease under discussion here.
In contrast to HPD, pseudoprogression is a transient lesion enlargement resulting from tumor infiltration with
immune cells during treatment with immunotherapy [38]. As first-line use of immunotherapies increases, it will be
important to avoid misattributing true PD as pseudoprogression, which could otherwise reduce patient access to
second-line therapies.
Prevalence of aggressive NSCLC
There is consistent evidence that a significant subpopulation of patients with nononcogene-addicted advanced
NSCLC derive little or no benefit from first-line chemotherapy. An early randomized study comparing four
platinum-based doublets reported a high rate of PD-FLT of 40–49%, with a correspondingly short median TTP of
3.1–4.2 months across the study arms [40]. Other trials of platinum combinations from the same era observed a lower
PD-FLT rate of 17–28% in patients unselected according to histology or biomarker expression [41–43]. More recent
estimates of the PD-FLT rate with chemotherapy are provided by the control arms of first-line immunotherapy
trials, which excluded patients with nonsquamous tumors and EGFR mutation/anaplastic lymphoma kinase (ALK)
rearrangement or required these patients to have received molecularly targeted therapy [11,12,15,16]. In these studies,
PD-FLT rates were reported at 17% with chemotherapy alone and 27% with chemotherapy plus bevacizumab in
nonsquamous populations, 14% with chemotherapy in squamous NSCLC, and 10% with chemotherapy alone in
patients with any histology and PD-L1 TPS ≥5% [11,12,15,16].
It is more challenging to extract time-based estimates of aggressive disease from these studies, since landmark
analyses of TTP or PFS at early time points have rarely been reported. TTP/PFS curves suggest that around 20–
30% of patients progress and/or die within 3 months of chemotherapy initiation [34,41]. Consistent with this, PFS
rates were estimated at 73 and 37% at 3 and 6 months, respectively, with cisplatin plus gemcitabine in a Phase III
study in squamous NSCLC [44]. A 6-month PFS rate of 50% was reported with chemotherapy alone in EGFR/ALK
wild-type NSCLC of any histology and PD-L1 TPS >50% in KEYNOTE-024 [10]. Prospective estimates of
aggressive disease prevalence are also provided by maintenance therapy trials in which response assessments after
four cycles of first-line treatment are used to determine eligibility for treatment de-escalation (Table 1). In these
studies, 14–31% of patients experienced progression after four cycles of induction therapy with platinum-based
doublets administered over 3–4 months [45–51].
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Table 1. Disease progression during induction therapy in maintenance trials in non-small-cell lung cancer.
Trial Histology n Induction regimen (no. cycles, cycle duration) PD rate at end of induction Ref.
IFCT-GFPC 0502 Any 834 Cisplatin + gemcitabine (four cycles, Q3W) 191/834 (23%) [45]
AVAPERL Nonsquamous 376 Cisplatin + pemetrexed + bevacizumab (four cycles,
Q3W)
52/376 (14%) [46]
Fidias 2008 Any 566 Carboplatin + gemcitabine (four cycles, Q3W) 147/566 (26%) [47]
PARAMOUNT Nonsquamous 939 Cisplatin + pemetrexed (four cycles, Q3W) 217/939 (23%) [48]
TITAN/SATURN Any 1949 Platinum-based doublets (four cycles, Q3W) 424/1949 (22%) [49]
Belani 2003 Any 401 Carboplatin + paclitaxel (four cycles, Q4W or two
cycles, Q8W)
NR/NR (31%) [50]
NR: Not reported; PD: Progressive disease; Q3W: Every 3 weeks; Q4W: Every 4 weeks; Q8W: Every 8 weeks.
Relevant data are also available from second-/third-line studies in which outcomes of prior therapy are retrospec-
tively assessed at enrollment and reported in baseline characteristics (Table 2). Although these patients represent
a more selected group (i.e., those for whom second-line therapy is considered suitable), they are the clinically
relevant population when considering the potential predictive relevance of first-line outcomes for subsequent treat-
ment strategies. Trials enrolling patients with any histological subtype who had previously received a single line
of chemotherapy have found prior PD-FLT rates of 20–30% in their respective populations [24,33,56,57,61,63]. In
second-line nonsquamous NSCLC, the rate of PD-FLT was 18% in the adenocarcinoma subgroup of LUME-
Lung 1 and 39% in CheckMate 057 [30,54]. TSFLT was <6 months in 25–35% of patients and <9 months in
43–62% of patients across the studies shown in Table 2 [24–26,30,33,37,60,62]. Approximately 70% of patients in these
studies had TEFLT ≤6 months [30,57]. As would be expected, in the adenocarcinoma population of LUME-Lung
1, the subgroup with TSFLT <9 months included almost all the patients with PD-FLT, but around two-thirds of
patients with TSFLT <9 months had attained at least disease stabilization during first-line chemotherapy [30].
Observational data suggest that similar numbers of patients fail to achieve disease control with initial chemother-
apy in less selected populations treated with a broader range of regimens [65–67]. In a German cohort of 804
patients with nonsquamous tumors, 48% discontinued first-line chemotherapy after just 1–3 cycles (C Grohe´,
Unpublished Observations).
The data above refer to first-line treatment with conventional chemotherapy regimens. Available data with
immunotherapies in this setting, alone or in combination with chemotherapy, are limited at present. In first-
line Phase III trials, PD-FLT rates with pembrolizumab plus chemotherapy versus chemotherapy alone were 9
versus 18% in nonsquamous NSCLC and 6 versus 14% in squamous tumors [11,16]. Results from ImPower150
indicate an 18% PD rate with atezolizumab in combination with bevacizumab plus chemotherapy in nonsquamous
EGFR/ALK wild-type NSCLC, compared with 27% in the control arm [12]. In the Phase III CheckMate 026 trial,
the rate of PD-FLT was numerically higher with nivolumab monotherapy (27%) than with chemotherapy alone
(10%) in patients with PD-L1 TPS ≥5% [15].
Prognosis of aggressive NSCLC
One of the first prospective datasets to associate aggressive disease during first-line therapy with outcomes in
subsequent lines was the randomized Phase III JMEI trial of second-line pemetrexed versus docetaxel [56,57]. In a
secondary analysis of both arms, patients with prior PD-FLT had significantly shorter median OS (4.6 months)
than patients with prior SD (10.5 months) or ORR (15.8 months) in univariate and multivariate analyses (both
p < 0.001) [57]. Median OS was also shorter in patients with TEFLT ≤3 months (6.9 months) than in patients
with TEFLT 3–6 months (9.2 months) or TEFLT ≥6 months (9.3 months; univariate p = 0.001), although this
was not significant after adjustment (p = 0.183) [57].
Subsequent studies have also highlighted a negative prognostic impact of aggressive disease behavior in first-line
treatment. In trial BR.21, which randomized patients ineligible for further chemotherapy to erlotinib or placebo
as second- or later-line therapy, both PD-FLT and time since diagnosis of <12 months were independently and
significantly correlated with shorter OS (p = 0.022 and p = 0.012, respectively) in the erlotinib arm [68]. Nonresponse
to prior chemotherapy was associated with a 25% increase in the risk of death in a meta-analysis of nine trials
of second-line chemotherapy, although the authors did not investigate PD-FLT specifically [69]. Poor outcomes
have been reported in second-line trials that selected a population with aggressive disease based on PD during or
immediately following induction therapy or TEFLT <3 months [37,49,67]. More recently, analyses of the control arm
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of LUME-Lung 2 identified TSFLT as potentially prognostic for both investigator-assessed and centrally assessed
PFS in patients receiving second-line pemetrexed [23].
Observational data support a prognostic impact of first-line outcomes on subsequent lines of therapy in real-world
settings [66,67,70]. For example, in a German nonsquamous cohort, earlier discontinuation of first-line chemotherapy
(after 1–3 cycles) was associated with both lower use and shorter duration of second-line treatment, as compared
with patients who had received 4–6 cycles of first-line therapy (C Grohe´, Unpublished Observations). Another
retrospective German study demonstrated a significant negative prognostic impact on OS of both PD-FLT and
TSFLT <9 months, with the latter also being shown for the adenocarcinoma population [67].
Demographic & clinical characteristics of patients with aggressive NSCLC
Few correlations between aggressive disease and demographic or clinical variables have been reported. Compared
with the overall populations, the TSFLT <9 months subgroup of LUME-Lung 1 and the PD-FLT subgroup of
REVEL had generally comparable baseline characteristics, although female patients may have been slightly under-
represented in the REVEL PD-FLT subgroup [24,25,30]. In a German observational study, failure to achieve disease
control with first-line treatment was associated with the presence of adrenal metastases, as well as the patient-related
poor prognostic factors of PS and self-reported weight loss at diagnosis [66].
Predictive relevance of aggressive NSCLC for efficacy of targeted therapies in second &
subsequent lines
Nintedanib
Nintedanib is an oral, small-molecule, triple angiokinase inhibitor of VEGFR 1–3, FGF receptor 1–3 and PDGF
receptor α/β, along with FLT3 and SRC family kinases [71]. It is approved in the EU for use in combination
with docetaxel for the second-line treatment of adenocarcinoma NSCLC based on the results of the Phase III
LUME-Lung 1 trial [33]. In that study, the addition of nintedanib to docetaxel significantly improved the primary
end point of PFS, compared with placebo plus docetaxel, in the overall population of 1314 patients previously
treated with a single line of chemotherapy (hazard ratio [HR]: 0.79; 95% CI: 0.68–0.92; p = 0.0019). A prespecified
key secondary end point analysis demonstrated a significant increase in OS favoring the nintedanib arm among
patients with adenocarcinoma histology (HR: 0.83; 95% CI: 0.70–0.99; p = 0.0359).
The nintedanib clinical development program in NSCLC provided the first evidence that prior aggressive tumor
behavior influenced the efficacy of a targeted therapy [23]. To identify potential clinical markers of nintedanib
treatment effect, the investigators undertook a systematic evaluation of data from LUME-Lung 1 along with a
second Phase III trial, LUME-Lung 2, which evaluated second-line nintedanib plus pemetrexed versus placebo plus
pemetrexed in advanced NSCLC [23,52]. In a hypothesis-generating stepwise selection and recursive partitioning
analyses of PFS data from LUME-Lung 2, TSFLT was significantly associated with prognosis in the placebo
arm and was the only prognostic variable also showing significant predictive relevance for PFS. HR by treatment
interaction plots suggested that a TSFLT cut-point of approximately 9 months provided an optimal binary split
for the predictive effect. Initial validation of the predictive relevance of TSFLT <9 months was provided by OS
data from LUME-Lung 2 and by centrally assessed PFS from LUME-Lung 1. In patients with adenocarcinoma
and TSFLT <9 months, median PFS in LUME-Lung 1 was 3.6 months in the nintedanib arm versus 1.5 months
with chemotherapy alone in the primary analysis (HR: 0.63; 95% CI: 0.48–0.83; p = 0.0008).
The predefined stepwise hierarchical testing of the key secondary end point of OS in LUME-Lung 1 revealed
a pronounced 3 month benefit in median OS with nintedanib plus docetaxel versus docetaxel alone in patients
with adenocarcinoma and TSFLT <9 months (medians: 10.9 vs 7.9 months; HR: 0.75; 95% CI: 0.60–0.92;
p = 0.0073) [23,33]. Exploratory analyses of the LUME-Lung 1 adenocarcinoma population also indicated a more
marked OS benefit of nintedanib in other aggressive disease subgroups, including TSFLT <5 or <6 months,
TEFLT <3 or ≤6 months, and PD-FLT [30,33]. Together, these results strongly suggest that adenocarcinoma
patients with the poorest outcomes during first-line therapy derive the greatest benefit from second-line treatment
with nintedanib in combination with docetaxel.
Ramucirumab
Ramucirumab is an anti-angiogenic monoclonal antibody against VEGFR2 that is approved for use in combination
with docetaxel for treatment of advanced NSCLC that has progressed following platinum-containing chemother-
apy [72]. In the primary end point analysis of the randomized Phase III REVEL study of 1253 patients with stage IV
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NSCLC, ramucirumab plus docetaxel significantly increased OS compared with placebo plus docetaxel medians:
10.5 vs 9.1 months; HR: 0.86; 95% CI: 0.75–0.98; p = 0.023) [24]. Prespecified subgroup analyses showed a signif-
icant OS treatment effect for ramucirumab in patients with TSFLT <9 months (HR: 0.75; 95% CI: 0.64–0.88),
which appeared greater than that in patients with TSFLT ≥9 months (HR: 0.95; 95% CI: 0.75–1.20) [24,25]. In
contrast to LUME-Lung 1, PD-FLT did not show clear evidence of a predictive effect for OS, with a similar HR
in this group and in patients with at least SD in first line [24,25].
Bevacizumab
The anti-VEGF monoclonal antibody bevacizumab is approved for use with first-line chemotherapy for non-
squamous advanced NSCLC [73]. Although not currently indicated in subsequent lines, bevacizumab has been
investigated in combination with weekly paclitaxel for second- or third-line treatment of nonsquamous NSCLC
in the Phase III IFCT-1103 ULTIMATE trial (n = 166) [26,73]. Analysis of the primary end point demonstrated
a significant increase in PFS with bevacizumab plus weekly paclitaxel compared with docetaxel alone (HR: 0.62;
95% CI: 0.44–0.87; p = 0.006), although there was no significant difference in OS. Subgroup analyses suggested
a more pronounced PFS treatment effect of bevacizumab plus weekly paclitaxel versus docetaxel in patients with
TSFLT <9 months (HR: 0.46; 95% CI: 0.26–0.84) than in patients with TSFLT ≥9 months (HR: 0.70; 95%
CI: 0.45–1.09).
Nivolumab
The PD-1 inhibitor nivolumab is approved for single-agent use for advanced NSCLC previously treated with
chemotherapy, following positive results from two separate randomized Phase III trials in PD-L1-unselected,
nonsquamous and squamous NSCLC (CheckMate 057 and 017, respectively) [54,5574]. In the primary analysis of
CheckMate 057 (n = 582), median OS was 12.2 months in the nivolumab arm and 9.4 months in the docetaxel
arm (HR: 0.73; 95% CI: 0.59–0.89; p = 0.002) [54]. The primary analysis of CheckMate 017 (n = 352) similarly
showed a significant OS benefit favoring the nivolumab arm (median OS: 9.2 vs 6.0 months; HR: 0.59; 95% CI:
0.44–0.79; p < 0.001) [55]. In nonsquamous NSCLC, PD-L1 level predicted efficacy of nivolumab versus docetaxel
in CheckMate 057, and no significant difference in OS was evident among patients with low or absent PD-L1
expression (TPS <1%) [54,75].
In contrast to results for anti-angiogenic therapies, prespecified subgroup analyses of CheckMate 057 showed
an apparent trend for greater OS benefit in patients with longer TEFLT (TEFLT >6 months; HR: 0.46; 95%
CI: 0.27–0.79) than in patients with aggressive disease (TEFLT <3 months [HR: 0.85; 95% CI: 0.67–1.08] or
3–6 months [HR: 0.69; 95% CI: 0.44–1.08]) [54]. A consistent trend was potentially also seen for TSFLT ≥12
versus <12 months. A striking observation from this study was the numerically higher mortality rate during the
first 3 months of follow-up in the nivolumab arm than in the docetaxel arm (20 vs 15%, respectively), which was
mostly due to PD-related deaths [27]. Post hoc exploratory multivariate analyses identified aggressive disease features
(TSFLT <3 months and PD-FLT), along with Eastern Cooperative Oncology Group PS of 1, as risk factors for
early mortality with nivolumab, when combined with low or absent PD-L1 expression [27].
Retrospective studies have provided some corroboration for these findings in real-world populations with
nonsquamous and squamous NSCLC, who received nivolumab in second or subsequent lines, irrespective of
PD-L1 expression [76–78]. In a Japanese study of 201 patients with nonsquamous or squamous NSCLC (any PD-L1
expression level) receiving nivolumab in second or later lines, 38 patients (19%) died within the first 3 months of
treatment [76]. Poor response to prior therapy was identified as an independent predictor of early death, along with
Eastern Cooperative Oncology Group PS ≥2 and high C-reactive protein-to-albumin ratio. Similarly, in a Spanish
retrospective study of nivolumab in second or subsequent lines of therapy in 175 patients with advanced NSCLC,
time since start of prior therapy of <6 months was significantly associated with poorer OS in multivariate analyses
(p = 0.010) [77]. This variable was also associated with shorter PFS and lower ORR. In a French retrospective cohort
of 115 patients, the disease control rate with nivolumab was significantly lower in those with PD-FLT than in
those who achieved at least SD during first-line therapy (60 vs 20%; p = 0.002) [78]. PD-FLT was also significantly
associated with shorter PFS and OS with nivolumab in multivariate analyses (p = 0.002 and p = 0.03, respectively).
Finally, Japanese retrospective data showed that the disease control rate with nivolumab was significantly lower in
patients with PD-FLT compared with those who previously achieved disease control with chemotherapy (35 vs
61%; p < 0.001) [79].
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Pembrolizumab
In addition to its first-line indications, the PD-1 inhibitor pembrolizumab is approved for use as monotherapy in
patients with previously treated advanced NSCLC and PD-L1 TPS ≥1%. In the Phase II/III KEYNOTE-010 trial
(n = 1034), the approved pembrolizumab dose (2 mg/kg) was associated with significant increases in the co-primary
end point of OS, both in the overall population and in patients with PD-L1 TPS ≥50%, when compared with
docetaxel alone [80]. Median OS in the overall population was 10.4 months with pembrolizumab versus 8.5 months
with docetaxel (HR: 0.71; 95% CI: 0.58–0.88; p = 0.0008). The second co-primary end point of PFS showed a
significant difference for pembrolizumab 2 mg/kg versus docetaxel in patients with PD-L1 TPS ≥50%, but not in
the overall population. Unlike CheckMate 057, no increase in early death was evident in the immunotherapy arms.
To our knowledge, no data have been presented regarding TSFLT or aggressive disease subgroups in this trial.
Atezolizumab
The most recently approved immunotherapy for NSCLC is the PD-L1 inhibitor atezolizumab, which is indicated
for single-agent use in patients with prior platinum chemotherapy [81]. In the co-primary end point analyses of the
first 850 patients randomized into the Phase III OAK trial, atezolizumab provided a significant increase in OS versus
docetaxel alone in both the overall population (median OS: 13.8 vs 9.6 months; HR: 0.73; 95% CI: 0.62–0.87;
p = 0.0003) and the population with PD-L1 expression on ≥1% of tumor cells or ≥1% of the tumor area infiltrated
by PD-L1-positive immune cells (15.7 vs 10.3 months; HR: 0.74; 95% CI: 0.58–0.93; p = 0.0102) [82]. Although
no association of atezolizumab with early death was evident, PFS was numerically shorter with atezolizumab than
with docetaxel during the first months of follow-up, an effect that appeared to be driven by patients with lower
PD-L1 expression. The potential relationship with features of prior aggressive disease behavior has not been reported
to our knowledge.
EGFR inhibitors
Phase III trials of second-/third-line treatment with EGFR inhibitors have been conducted in aggressive disease
populations but lack contemporary relevance due to their EGFR-unselected populations [37,49]. The ISEL study
showed no significant difference in OS with gefitinib versus placebo in patients with progression or recurrence within
90 days of prior chemotherapy completion or intolerance to prior chemotherapy [37]. In patients with progression
on or after four cycles of induction chemotherapy in the TITAN study, there was no significant difference in OS
with erlotinib compared with docetaxel or pemetrexed [49]. Finally, OS with gefitinib versus docetaxel did not appear
to differ according to TSFLT or PD-FLT subgroups in EGFR-unselected patients in the Phase III INTEREST
trial [60].
Pathophysiology of aggressive NSCLC
The mechanistic basis of platinum resistance is complex and multifactorial [83]. Predominantly based on in vitro stud-
ies, several resistance mechanisms have been described, including poor drug uptake due to low copper transporter-1
expression, drug detoxification resulting from high glutathione S-transferase M1 activity and resistance to apoptosis
via overexpression of prosurvival factors (e.g., B-cell lymphoma protein-2 or serpin B3) [7,84,85]. Some of the most
extensively studied molecular determinants of platinum resistance involve components of the DNA repair path-
ways that can reverse the intra- and interstrand crosslinks introduced by platinum compounds [7,84,86]. Expression
and/or genetic polymorphisms in ERCC1, BRCA1 and RRM1 have been correlated with outcomes of platinum-
based chemotherapy, but none of these biomarkers have so far been prospectively validated for predictive use [86].
Chemoresistance has also been associated with certain rare NSCLC histological subtypes, including sarcomatoid
carcinomas and invasive mucinous adenocarcinomas, although this may be partly anecdotal [87,88].
Rapid progression of NSCLC is likely to be reflected in a high rate of cellular proliferation within the tumor. This
is supported by a gene-set enrichment analysis of robust multi-array normalized gene expression data from a large
database generated by the Director’s Challenge Consortium for the Molecular Classification of Adenocarcinoma [89].
In that dataset, proliferation-related genes were more frequently expressed in patients with shorter OS compared
with those who survived for longer after diagnosis. Consistent with this, the proportion of proliferating tumor cells,
assessed according to expression of the proliferation marker Ki-67, has been associated with tumor size and nodal
stage, as well as shorter OS in patients with adenocarcinoma NSCLC [90].
One of the consequences of rapid cancer growth is the development of a hostile tumor microenvironment
characterized by hypoxia, low nutrient levels and acidification of the extracellular milieu [91–93]. Hypoxia, in
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particular, is thought to be a critical factor in the development of aggressive tumor characteristics [91,93]. Although
intratumoral hypoxia may retard or limit cancer growth, it also triggers adaptive mechanisms that help to establish
a vicious circle by promoting further tumor progression [94]. A well-characterized response to hypoxia is the
upregulation of angiogenic factors, including VEGF, PDGF and FGF, which stimulate the formation of new
vasculature. Rapidly progressing tumors may, therefore, be particularly dependent on this process for the delivery
of adequate oxygen and nutrients, and so be more sensitive to anti-angiogenic therapies [23,30].
Furthermore, severe hypoxia can promote genomic instability while enhancing selective pressure, which may in
turn foster the emergence of aggressive tumor characteristics, including chemoresistance and increased propensity
to metastasize [94]. A number of microRNAs have been implicated in hypoxia-induced platinum resistance in
NSCLC [83]. At the same time, hypoxia has been shown to modulate the immunological character of the microen-
vironment such that antitumor immunity may be downregulated [93]. VEGF, in addition to its pro-angiogenic
properties, has several immunosuppressive actions, including inhibiting the maturation of granulocyte-macrophage
and dendritic cell precursors and inhibiting the recruitment of M2 macrophages [93]. Thus, hypoxia and its down-
stream effects could be a key mechanism linking platinum resistance, sensitivity to anti-angiogenics and poor
response to immunotherapies.
Clinical implications & definition of aggressive NSCLC
Treatment selection
At present, the most clinically relevant findings regarding aggressive NSCLC relate to its predictive potential for
second-line targeted therapies (Table 3). TSFLT <9 months has been prospectively validated to identify patients
who derive more pronounced benefit of nintedanib with second-line docetaxel for adenocarcinoma NSCLC,
and the treatment effect appeared to increase still further with shorter TSFLT durations [23,30,33]. Exploratory
analyses indicate this positive predictive relevance may similarly apply for other anti-angiogenic therapies, namely
ramucirumab (irrespective of tumor histology) and bevacizumab (in nonsquamous NSCLC) [24–26,30,33]. The
consistent signal across three independent Phase III trials suggests that neoangiogenesis plays a more important role
in more rapidly progressing or aggressive lung tumors, but further data are required to confirm this dependency.
Conversely, features of aggressive disease have been associated with poor outcome with second-line nivolumab
in patients with nonsquamous tumors and low or absent tumor PD-L1 expression, and in less selected real-world
populations [27,76–78]. Some caution is required when interpreting the opposing directions of this effect with
nivolumab relative to the anti-angiogenic compounds nintedanib, ramucirumab and bevacizumab. Many of the
analyses are exploratory and/or post hoc and the apparent disparity may be explained by differences in patient
populations. Furthermore, relevant data are available from only a single immunotherapy trial (CheckMate 057)
and the impact of aggressive disease on other immunotherapies, such as pembrolizumab, requires further evaluation.
Nonetheless, it has been suggested that anti-angiogenic therapies might be favored over immunotherapies in the
second-line treatment of nonsquamous NSCLC with low PD-L1 expression and fast progression or lack of disease
control with first-line platinum-containing therapy [95]. Such an approach has some precedent given the importance
of platinum sensitivity in clinical decision making for other tumor types, including SCLC and ovarian cancer [96].
Although this treatment paradigm emerged from the correlation between the duration of the platinum-free interval
and sensitivity to platinum rechallenge, its predictive relevance extends beyond platinum agents to other drugs with
different mechanisms of action [97].
Defining aggressive NSCLC
One challenge in the clinical implementation of such a management model is the lack of accepted definition
of aggressive NSCLC. The wide variety of definitions utilized so far specify distinct but overlapping subgroups,
underscoring a need to develop consensus criteria by which patients with aggressive disease can be optimally
identified. Based on a thorough review of the available clinical data, we recommend defining aggressive nonsquamous
NSCLC based on TSFLT <6–9 months. Although the 9 month cut-off represents the best studied definition to date
(Table 3), clinical observations of the authors suggest that the 6-month cut-off may be most useful for identifying
this subgroup in practice. Published evidence and clinical experience to date indicate this criterion would identify
a substantial proportion of patients in current clinical practice, whether treated in the first-line with chemotherapy
alone, immunotherapy alone or regimens combining these modalities. In addition to the predictive considerations
discussed above, these patients may benefit from intensified monitoring (e.g., every 2 weeks) due to the aggressive
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course of disease. It is likely that this patient population has a separate disease entity with a distinct genetic or
immunological background, which requires further biologic and clinical investigation.
Future directions
Current definitions of aggressive NSCLC based on response to initial therapy do not enable up-front patient
identification, nor do they distinguish between aggressive underlying disease and treatment refractoriness. These
central limitations may be addressed through careful clinical, pathological and molecular characterization of patients
with aggressive disease in order to improve our understanding of the biological determinants of treatment resistance,
as well as the factors driving de novo aggressive disease behavior. One key goal will be the development of novel
molecular or pathologically assessable morphological markers that can predict rapid disease progression and thereby
enable appropriately tailored management from diagnosis.
Our clinical definition of aggressive disease can support this endeavor by harmonizing research based on more
uniform populations of patients with rapidly progressing disease. Given the mounting evidence that aggressive
disease has both prognostic and predictive relevance, we recommend that future studies should prespecify analyses
of this aggressive disease subgroup. In this respect, results are keenly awaited from the ongoing noninterven-
tional LUME-BioNIS study, which is investigating associations between a wide range of biomarkers and TSFLT
<9 months in patients receiving nintedanib in line with the approved label [98]. Ultimately, it will be of interest
to evaluate novel treatment strategies for this patient group, such as early anti-angiogenic therapy plus a taxane or
combinations of anti-angiogenic agents with immunotherapies.
Conclusion
It is clear that a substantial subpopulation of patients with nononcogene-addicted advanced NSCLC have an
aggressive course of disease, with resistance to first-line platinum doublets or immunotherapy with or without
chemotherapy. These patients have been under-recognized to date and have a high unmet medical need for new
treatment options that could transform their poor prognosis. Emerging data suggest that features of aggressive disease
differentially impact on the efficacy of some targeted therapies in the second-line setting. Further investigations
are required to improve our understanding of the pathophysiological mechanisms driving aggressive disease, which
may represent a distinct disease entity. Our proposed definition of aggressive NSCLC can support research aiming
to advance the care of this neglected patient subgroup.
Future perspective
Over the next 5–10 years, better understanding of the molecular biology of NSCLC will continue to drive the
division of the disease into different subtypes, with a consequent increase in the complexity of management and
therapeutic considerations. To fully exploit the new opportunities for personalized medicine, clinical trial designs will
require adaptation to enable meaningful analyses of large numbers of potentially prognostic and predictive factors.
In this respect, alongside novel molecular predictors, clinical variables such as TSFLT <9 months may be valuable.
In addition to new molecular biomarkers, the development of novel pathologically assessable morphological markers
may help address the urgent need to enable up-front identification of chemoresistant and/or aggressive disease. We
anticipate that improved definition and recognition of this patient subgroup will ultimately expand the available
range of effective strategies, which may include novel combinations and/or rational treatment sequencing.
Executive summary
• Platinum-based chemotherapy was for many years the mainstay of first-line treatment for nononcogene-addicted
non-small-cell lung cancer (NSCLC); however, the treatment paradigm is currently evolving with the incorporation
of immunotherapies into this setting.
• Platinum doublets provide an overall response rate of 20–30% and median time to progression of
3.5–5.5 months, but almost all patients will eventually develop progressive disease.
• Second-line options can include anti-angiogenic agents (nintedanib or ramucirumab) plus docetaxel, single-agent
immunotherapies (pembrolizumab, nivolumab or atezolizumab) or cytotoxic monotherapy (docetaxel and
pemetrexed), depending on first-line therapy, tumor histology and PD-L1 expression.
• Recently, clinical correlates of aggressive disease behavior during first-line treatment have been shown to predict
greater benefit of second-line nintedanib in combination with docetaxel in patients with adenocarcinoma NSCLC.
The predictive relevance may also extend to other agents.
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• Despite its emerging predictive significance, there is no standard definition of ‘aggressive NSCLC’ and these
patients represent an under-recognized and neglected population who have poor outcomes with current therapy.
Concept of aggressive NSCLC
• ‘Aggressive disease’ refers to tumors that develop, progress or metastasize more quickly, manifesting as poor
clinical outcomes, including lack of disease control and shorter time to progression.
• Analyses to date have defined aggressive disease subgroups based on shorter time since start of first-line therapy
(TSFLT, with <9 months as the most commonly used cut-point), time since end of first-line therapy or progressive
disease as best response to first-line therapy (PD-FLT).
• The term ‘hyperprogressive disease’ refers to the paradoxical acceleration of tumor growth during treatment
with immunotherapies, relative to the pretreatment period.
Prevalence of aggressive NSCLC
• A body of evidence indicates that a significant proportion of patients with NSCLC derive no or only limited
benefit from first-line chemotherapy.
• Control arms of recent first-line immunotherapy studies demonstrate a 10–27% rate of PD-FLT with
platinum-based doublets in patient populations selected according to tumor histology and molecular
characteristics.
• In maintenance therapy trials, 14–31% of patients had progressive disease after 3–4 months of platinum-based
induction chemotherapy.
• Baseline data from recent second-line trials indicate thatup to 62% of patients have TSFLT <9 months and up to
39% have PD-FLT in populations considered suitable for further therapy.
Prognosis of aggressive NSCLC
• Both randomized controlled trials and observational studies indicate that aggressive disease during first-line
therapy has a negative prognostic impact on outcomes in subsequent treatment lines.
Demographic & clinical characteristics of patients with aggressive NSCLC
• Few studies have reported correlations between aggressive disease and demographic or clinical variables.
• Lack of disease control in first-line treatment has been associated with the presence of adrenal metastases, poor
performance status and weight loss at diagnosis in an observational study.
Predictive relevance of aggressive NSCLC for efficacy of targeted therapies in second & subsequent lines
• The predictive relevance of aggressive disease was first highlighted in a systematic evaluation of LUME-Lung 2,
which identified TSLFT <9 months as a potential positive predictive marker for nintedanib in combination with
second-line chemotherapy.
• TSFLT <9 months was subsequently confirmed to predict the treatment effect of second-line nintedanib plus
docetaxel versus placebo plus docetaxel in a prespecified analysis of overall survival (OS) in patients with
adenocarcinoma histology in LUME-Lung 1.
• The addition of nintedanib to docetaxel provided a pronounced 3 month benefit in median OS (median of 10.9
vs 7.9 months with docetaxel alone; hazard ratio: 0.75; 95% CI: 0.60–0.92; p = 0.0073). Exploratory analyses also
showed a more marked OS benefit of nintedanibin other aggressive disease subgroups including patients with
PD-FLT.
• These observations have since been extended in subgroup analyses of other Phase III trials, which suggest that
TSFLT <9 months also predicts greater efficacy of ramucirumab in combination with docetaxel (REVEL; any
histology) and bevacizumab plus weekly paclitaxel (ULTIMATE; nonsquamous histology).
• Conversely, aggressive disease features (TSFLT <3 months and PD-FLT), along with poorer performance status,
were identified as risk factors for early mortality with nivolumab, when combined with low or absent PD-L1
expression in an exploratory analysis in nonsquamous NSCLC (CheckMate 057).
• To our knowledge, no aggressive disease subgroup data have been reported for second-line trials of
pembrolizumab or atezolizumab.
Pathophysiology of aggressive NSCLC
• Proposed chemoresistance mechanisms include poor drug uptake due to low copper transporter-1 expression,
drug detoxification resulting from high glutathione S-transferase M1 activity, and resistance to apoptosis via
overexpression of prosurvival factors.
• Due to a rapid rate of cellular proliferation, aggressive tumors might be particularly dependent on
neoangiogenesis for the delivery of adequate oxygen and nutrients, which may in turn sensitize them to
anti-angiogenic therapies.
Clinical implications & definition of aggressive NSCLC
• Given the opposing directions of the predictive effect of aggressive disease for anti-angiogenic therapies (plus a
taxane) compared with nivolumab, it has suggested that anti-angiogenic therapy may be preferred over
immunotherapies in the second-line treatment of nonsquamous NSCLC with low PD-L1 expression.
• We recommend defining aggressive nonsquamous NSCLC based on TSFLT <6–9 months, which is expected to
identify a substantial proportion of patients in current practice, irrespective of initial treatment type.
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• Further investigation is required to elucidate the pathophysiological basis of aggressive disease behavior and
identify novel molecular and/or pathologically assessable morphological markers to enable up-front patient
recognition.
Conclusion
• A substantial proportion of advanced NSCLCs shows aggressive disease behavior during first-line therapy, which is
associated with a poor prognosis and may differentially impact on the efficacy of second-line targeted therapies.
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